Sector News

Gilead investing £19.6 million into UK expansion

February 10, 2015
Life sciences
Gilead Sciences is to create new UK commercial headquarters in London and expand its existing operations in the country.
The US biotech major is setting up home in Holborn and expanding its international operations in Uxbridge and UK R&D headquarters in Cambridge. The moves represent an increased investment of $19.6 million, doubling Gilead’s UK workforce to 600 by the end of the year – 400 will be based in London.
Boston-based Gilead’s investment was announced by Mayor of London Boris Johnson on US trade mission to drum up new business for the capital. The announcement comes less than a year since he launched MedCity, which aims to help the life sciences industry in London and the greater south east of England.
Mayor Johnson also announced that another Boston-based company Mobiquity, which specialises in mobile health, is investing £13 million over the next two years in a new London base. He said that Gilead and Mobiquity’s moves to London “further underline the growing importance of the life sciences industry in the UK as we look to ensure that this crucial sector becomes a key contributor to the capital’s growth and health”.
In November, Merck & Co announced a £42 million investment to create a new London licensing hub, expand research in Hertfordshire and fund clinical research in oncology and dementia. Pfizer is setting up a new gene therapy unit in the capital focused on rare diseases.
By Kevin Grogan

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]